AU6686596A - Pain-alleviating drug composition and method for alleviating pain - Google Patents

Pain-alleviating drug composition and method for alleviating pain

Info

Publication number
AU6686596A
AU6686596A AU66865/96A AU6686596A AU6686596A AU 6686596 A AU6686596 A AU 6686596A AU 66865/96 A AU66865/96 A AU 66865/96A AU 6686596 A AU6686596 A AU 6686596A AU 6686596 A AU6686596 A AU 6686596A
Authority
AU
Australia
Prior art keywords
pain
alleviating
drug composition
analgesic
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66865/96A
Inventor
John W Lyle
Jianren Mao
David J Mayer
Donald D Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of AU6686596A publication Critical patent/AU6686596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The analgesic effectiveness of a combination drug composition containing at least one analgesic is significantly enhanced by the addition of a nontoxic N-methyl-D-aspartate (NMDA) receptor antagonist thereto.
AU66865/96A 1995-08-02 1996-07-31 Pain-alleviating drug composition and method for alleviating pain Abandoned AU6686596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/510,546 US5840731A (en) 1995-08-02 1995-08-02 Pain-alleviating drug composition and method for alleviating pain
US510546 1995-08-02
PCT/US1996/012597 WO1997004780A2 (en) 1995-08-02 1996-07-31 Pain-alleviating drug composition and method for alleviating pain

Publications (1)

Publication Number Publication Date
AU6686596A true AU6686596A (en) 1997-02-26

Family

ID=24031191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66865/96A Abandoned AU6686596A (en) 1995-08-02 1996-07-31 Pain-alleviating drug composition and method for alleviating pain

Country Status (11)

Country Link
US (3) US5840731A (en)
EP (1) EP0845989B1 (en)
JP (1) JP3924321B2 (en)
AT (1) ATE214277T1 (en)
AU (1) AU6686596A (en)
CA (1) CA2228249C (en)
DE (1) DE69619832T2 (en)
DK (1) DK0845989T3 (en)
ES (1) ES2170865T3 (en)
PT (1) PT845989E (en)
WO (1) WO1997004780A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2291335A1 (en) 1997-05-27 1998-12-03 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
EP0906757B1 (en) * 1997-09-16 2005-05-11 Solvay Pharmaceuticals GmbH Analgesic composition comprising moxonidine and an opioid analgesic agent
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
BR9912827A (en) * 1998-07-16 2001-05-02 Sloan Kettering Inst Cancer Topical compositions comprising an opioid analgesic and an nmda antagonist
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
WO2001082914A2 (en) 2000-04-28 2001-11-08 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
EP1292307A2 (en) * 2000-06-09 2003-03-19 The Regents of The University of California Method of treating pain using nalbuphine and opioid antagonists
JP2005506292A (en) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ pH-dependent NMDA receptor antagonist
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
AR034362A1 (en) * 2001-06-05 2004-02-18 Control Delivery Systems ANALGESIC PROLONGED RELEASE COMPOUNDS
EP1395289B1 (en) * 2001-06-07 2010-12-15 Christine Dr. Sang Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
EP1415482A1 (en) * 2001-07-27 2004-05-06 Koninklijke Philips Electronics N.V. Autostereoscopic image display with observer tracking system
AU2002336653A1 (en) * 2001-10-24 2003-05-06 Luciano Mastronardi Management of postoperative pain
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
JP4865330B2 (en) * 2002-12-13 2012-02-01 デュレクト コーポレーション Oral drug delivery system
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
US20040259809A1 (en) * 2003-06-17 2004-12-23 Pediamed Pharmaceuticals, Inc. Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
EP1817023A4 (en) * 2004-11-16 2010-08-18 Limerick Biopharma Inc Methods and compositions for treating pain
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
AU2007225022A1 (en) * 2006-03-15 2007-09-20 Biotech Pharmaceuticals Pty Ltd Non-codeine opioid analgesic process and formulations
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
US8034801B2 (en) 2006-07-12 2011-10-11 Aska Pharmaceutical Co., Ltd. Analgesic agent
SI2124556T1 (en) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Pharmaceutical compositions
CN103058957A (en) 2007-06-29 2013-04-24 埃莫里大学 NMDA receptor antagonists for neuroprotection
US20090110724A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US20090191257A1 (en) * 2008-01-29 2009-07-30 Innovative Pharmaceuticals, Llc Pain relief lollipop compositions and methods
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
KR20140014350A (en) * 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 Administration of intravenous ibuprofen
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
KR102016305B1 (en) 2011-11-07 2019-08-30 넥타르 테라퓨틱스 Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
TW201521769A (en) 2013-03-15 2015-06-16 Durect Corp Compositions with a rheological modifier to reduce dissolution variability
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
TW202348234A (en) 2013-12-24 2023-12-16 維吉尼亞聯邦大學 Uses of oxygenated cholesterol sulfates (ocs)
AU2015277053B2 (en) 2014-06-20 2020-01-23 Lohocla Research Corporation Multifunctional aminoquinoline therapeutic agents
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11214544B2 (en) 2017-04-14 2022-01-04 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP2022523510A (en) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド Particle formation and morphological structure
WO2021050953A1 (en) 2019-09-13 2021-03-18 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316888A (en) * 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) * 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
CA1194799A (en) * 1981-12-10 1985-10-08 Eric L. Nelson Method and composition for reducing menstrual pain
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
CA1267092A (en) * 1985-02-25 1990-03-27 Martin D. Hynes Analgesic composition containing codeine
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5013540A (en) * 1989-11-30 1991-05-07 Board Of Regents, The University Of Texas System Using NMDA receptor antagonists to reduce damage due to laser treatment
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
DE69226624T3 (en) * 1991-09-06 2009-11-05 Ortho-Mcneil Pharmaceutical, Inc. COMPOSITION CONTAINING A TRAMADOL COMPOUND AND ACETAMINOPHES, AND ITS USE
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
US5348747A (en) * 1992-03-05 1994-09-20 American Home Products Corporation Pharmaceutical coating sugars
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP0778770B1 (en) * 1994-09-02 2003-12-10 Virginia Commonwealth University Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer

Also Published As

Publication number Publication date
PT845989E (en) 2002-07-31
CA2228249A1 (en) 1997-02-13
CA2228249C (en) 2002-12-03
WO1997004780A2 (en) 1997-02-13
EP0845989A2 (en) 1998-06-10
EP0845989B1 (en) 2002-03-13
JPH11512081A (en) 1999-10-19
ES2170865T3 (en) 2002-08-16
WO1997004780A3 (en) 1997-03-27
ATE214277T1 (en) 2002-03-15
JP3924321B2 (en) 2007-06-06
US5863922A (en) 1999-01-26
DE69619832T2 (en) 2002-10-31
DK0845989T3 (en) 2002-04-29
DE69619832D1 (en) 2002-04-18
US5840731A (en) 1998-11-24
US5869498A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
AU6686596A (en) Pain-alleviating drug composition and method for alleviating pain
EP0938305B8 (en) Method of alleviating pain by means of combining tramadol with an nmda antagonist
AU4078897A (en) Anticonvulsant containing composition for treating neuropathic pain
AU2636797A (en) Fast disintegrating oral dosage form
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
MY115662A (en) Novel compounds with analgesic effect
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
MX9706449A (en) Pharmaceutical composition for piperidinoalkanol compounds.
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
UA41392C2 (en) Rapidly soluble tablet of tramadol or tramadol salt
NZ292429A (en) Combination of non-narcotic analgesic and nmda receptor antagonist for alleviating pain
BG103369A (en) Method for the prevention of the cancer of the breast
GEP20063719B (en) Prevention of Migraine Recurrence
MX9708557A (en) New pharmacological use of aii-receptor antagonists.
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
MX9702253A (en) Novel estrenes for inducing hypothalamic effects.
LTIP1958A (en) New use of ropivacaine
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
UA41981C2 (en) Biotin compounds, a PROCESS for the preparation thereof, a pharmaceutical composition and a PROCESS for the preparation thereof
MX9605604A (en) New agonist compounds.
MX9804797A (en) Novel compounds with analgesic effect.
MX9705324A (en) Transdermal therapeutic system for dispensing (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts.